Drugs / AGA111
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05574543 | Dec 2020 → Jul 2022 | intervertebral disk degenerative disorder | Angitia Biopharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06115512 | Dec 2023 → Nov 2025 | intervertebral disk degenerative disorder | Angitia Biopharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGA111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06115512 ↗ |
| Route | Other | “AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.” NCT05574543 ↗ |